(Q39989085)

16 September 2017

title

MCP-1 and IL-8 as pain biomarkers in fibromyalgia: a pilot study (English)

1 reference

16 September 2017

0 references

0 references

Dennis C Ang

1

1 reference

16 September 2017

Michele N Moore

series ordinal

2

1 reference

16 September 2017

Janna Hilligoss

series ordinal

3

1 reference

16 September 2017

Rebeka Tabbey

series ordinal

4

1 reference

16 September 2017

publication date

30 June 2011

1 reference

16 September 2017

1 reference

16 September 2017

volume

12

1 reference

16 September 2017

issue

8

1 reference

16 September 2017

page(s)

1154-1161

1 reference

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Evoked pain measures in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Blunted ACTH and cortisol responses to systemic injection of corticotropin-releasing hormone (CRH) in fibromyalgia: role of somatostatin and CRH-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Neuropeptides activate human mast cell degranulation and chemokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Expression of monocyte chemoattractant protein-1 in rat dorsal root ganglia and spinal cord in experimental models of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Neuroendocrine immunology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Assessing global pain severity by self-report in clinical and health services research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Validation of the Brief Pain Inventory for chronic nonmalignant pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

The PHQ-8 as a measure of current depression in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Do the PHQ-8 and the PHQ-2 accurately screen for depressive disorders in a sample of pregnant women?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Physical therapy modalities in management of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Status of immune mediators in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

The role of IL-8 in patients with fibromyalgia: a prospective longitudinal study of 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Mast cells as targets of corticotropin-releasing factor and related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Mast cells are involved in inflammatory reactions during Complex Regional Pain Syndrome type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Serum chemokine levels in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4637.2011.01179.X

10.1111/J.1526-4637.2011.01179.X

21 January 2018

Identifiers

DOI

1 reference

release_g2jgg6466rgexbkmcyzm6eqy6m

16 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g2jgg6466rgexbkmcyzm6eqy6m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference